Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given an average rating of "Buy" by the eight research firms that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $7.00.

Several research firms recently weighed in on TSHA. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. JMP Securities lifted their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research report on Thursday. Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Finally, Chardan Capital lifted their price target on Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Thursday.

Taysha Gene Therapies Stock Up 12.7%

Taysha Gene Therapies stock traded up $0.31 during mid-day trading on Friday, reaching $2.75. The company's stock had a trading volume of 22,170,446 shares, compared to its average volume of 2,993,969. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $4.32. The business's 50 day simple moving average is $1.90 and its 200 day simple moving average is $1.90. The company has a market capitalization of $590.32 million, a price-to-earnings ratio of 4.37 and a beta of 0.90.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. During the same period in the prior year, the firm posted ($0.10) earnings per share. As a group, research analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Ground Swell Capital LLC acquired a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Cibc World Markets Corp acquired a new position in Taysha Gene Therapies in the 4th quarter valued at $28,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies during the 4th quarter worth $31,000. Hsbc Holdings PLC increased its position in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after buying an additional 8,076 shares during the period. Finally, AXQ Capital LP acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $39,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.